menu
    • menu
    [{"orgOrder":0,"company":"Endo Pharm","sponsor":"Mallinckrodt Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"IRELAND","productType":"Other Small Molecule","year":"2025","type":"Merger","leadProduct":"Aliskiren","moa":"Renin","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Endo Pharm","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Endo Pharm \/ Mallinckrodt Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Endo Pharm \/ Mallinckrodt Pharmaceuticals"}]

    Find Clinical Drug Pipeline Developments & Deals for Aliskiren

    Menu

    Aliskiren

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    DRUG PRODUCT COMPOSITIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Endo Pharm

                            Ireland arrow
                            IOPC
                            Not Confirmed

                            Endo Pharm

                            Ireland arrow
                            IOPC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Aliskiren

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Approved FDF

                            Sponsor : Mallinckrodt Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Merger

                            DEALS_DEV arrow-down

                            Mallinckrodt and Endo Announce Significant Progress in Proposed Merger

                            Details : Under the merger agreement, the combined generic businesses & Endo's injectables business will form a new standalone entity, which includes Tekturna-Generic (aliskiren hemifumarate) for hypertension.

                            Product Name : Tekturna-Generic

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            May 13, 2025

                            Lead Product(s) : Aliskiren

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Approved FDF

                            Sponsor : Mallinckrodt Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Merger

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth